AbbVie stock slides 2% as obesity push takes center stage at JPM conference
AbbVie shares dropped 2.1% to $217.13 Thursday following the company’s expanded plans for obesity treatments announced at the J.P. Morgan Healthcare Conference.
Johnson & Johnson stock slips as Tecvayli trial data lands ahead of earnings week
Johnson & Johnson shares dipped Thursday following fresh late-stage data release for its Tecvayli cancer drug, with investors also bracing for next week’s earnings report.
GSK stock rises as pipeline talk hits JPM conference, with Feb. 4 earnings in focus
GSK plc’s shares traded in the U.S. climbed 1.8% on Wednesday, closing at $50.79. The stock remains in the spotlight heading into Thursday’s session.
Merck stock rises as $70 billion growth target sharpens focus ahead of Feb. 3 earnings
Merck & Co shares closed Wednesday up 2.54% at $111.01, rebounding from a short dip and holding close to recent peaks ahead of Thursday’s trading.
AbbVie stock in focus after hours as it eyes obesity market — what to watch next
AbbVie Inc’s shares climbed roughly 0.5% to $221.89 in after-hours trading Wednesday, following executives’ announcement to expand the company’s footprint in obesity treatments. During the regular session, the stock fluctuated between $217.84 and $223.27.
Pfizer stock rises as CEO bets on “Viagra-like” obesity demand; what investors watch next
Shares of Pfizer climbed Wednesday as investors focused on the company’s move into obesity treatments, now the key battleground in the pharmaceutical sector.
Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push
Eli Lilly shares slipped in after-hours trading Wednesday, as investors digested a U.S. regulatory update on weight-loss drug labels alongside new marketing chatter about the company’s upcoming obesity treatment.
Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings
Johnson & Johnson shares climbed 2.3% to $218.55 in after-hours trading Wednesday following upbeat topline data from a late-stage multiple myeloma study for Tecvayli.
Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus
Pfizer Inc shares climbed about 2% to $25.65 on Wednesday following CEO Albert Bourla’s remarks on the company’s push into the rapidly expanding cash-pay obesity drug market. “We are all in on obesity,” Bourla told reporters at the J.P. Morgan Healthcare Conference. Pfizer plans to launch 10 Phase 3 trials for its Metsera obesity compounds by the end of 2026, aiming to fuel future growth. The company still doesn’t expect revenue growth to return until 2029, as it navigates patent expirations and a slowdown in COVID-era sales.
Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline
Viridian Therapeutics shares climbed 6.4% to $34.03 in early afternoon trading on Wednesday, after hitting an intraday high of $34.25, a new 52-week peak.
Nuvalent stock jumps as FDA review clock sharpens focus on 2026 launch plans
Nuvalent’s stock climbed roughly 6% Wednesday afternoon, building on earlier gains as the biotech detailed crucial 2026 goals for its lead lung-cancer project and highlighted a sizable cash pile expected at year-end.
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names
Shares of Structure Therapeutics jumped roughly 7.5% Wednesday, as traders returned to small-cap obesity drugmakers. The stock climbed to $83.76, trading over 1 million shares.
Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map
Terns Pharmaceuticals shares jumped over 10% Wednesday, fueled by the company’s newest conference update on its lead cancer drug. By midday, the stock had risen 10.4% to $38.03, after trading in a range from $34.05 to $38.35.
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings
Pfizer Inc shares climbed Wednesday following CEO Albert Bourla’s renewed commitment to fast-track obesity drugs, a crucial focus as the company navigates patent losses and adjusts post-COVID.
Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next
Eli Lilly and Company shares slipped Wednesday following a move by U.S. regulators to remove suicide-related warnings from several popular obesity drugs, including Lilly’s Zepbound. The stock was down roughly 0.4%, trading near $1,072.89 by late morning.
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom
Johnson & Johnson shares climbed 1.9% to $217.80 by late morning Wednesday, defying the SPDR S&P 500 ETF, which dipped roughly 1%.
Gelteq Limited stock jumps in premarket after CBD gel study; what’s next for GELS
Gelteq Limited shares surged roughly 48% to $1.23 in premarket action Wednesday, following a 6.4% gain at Tuesday’s close.
NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset
NRx Pharmaceuticals shares dropped 4.3% to $2.13 in premarket on Wednesday. The FDA granted Fast Track status to NRX-100, the company’s preservative-free ketamine treatment targeting suicidal ideation. NRx plans to submit real-world data from over 70,000 patients to back an accelerated approval application. CEO Jonathan Javitt noted, “An American commits suicide every 11 minutes.”
FTSE 100 climbs on miners and AstraZeneca as record gold keeps UK stocks in play
Britain’s FTSE 100 rose 0.3% to 10,170.81 in mid-morning trade, helped by gold-linked miners and a lift in AstraZeneca. Endeavour Mining gained 3.4%, AstraZeneca rose 2.6% and Glencore added 2.3%, while the index came into the day after edging down 0.03% on Tuesday.
Viatris stock steadies in premarket after a 5% jump on JPM conference remarks — what investors watch next
Viatris Inc shares showed little movement in premarket trading Wednesday, following a more than 5% jump the day before. The stock was indicated near $13.37.
TechStock² Updates
